Articles with public access mandates - Thorvardur HalfdanarsonLearn more
Not available anywhere: 4
Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver
XM Keutgen, E Schadde, RF Pommier, TR Halfdanarson, JR Howe, ...
Seminars in oncology 45 (4), 232-235, 2018
Mandates: US National Institutes of Health
Renal neuroendocrine neoplasms: a single-center experience
PW McGarrah, GFM Westin, TJ Hobday, JA Scales, JP Ingimarsson, ...
Clinical genitourinary cancer 18 (4), e343-e349, 2020
Mandates: US National Institutes of Health
Efficacy of first‐line checkpoint inhibitors in combination with chemotherapy in high‐grade extrapulmonary metastatic neuroendocrine carcinomas
JJ Gile, PW McGarrah, K Leventakos, MB Sonbol, JS Starr, RA Eiring, ...
Journal of Neuroendocrinology 35 (5), e13283, 2023
Mandates: US National Institutes of Health
Biomarkers for prognosis in pancreatic neuroendocrine tumors
M Zhu, KR Sorenson, R Liu, BEG Rothberg, TR Halfdanarson
Endocrine-Related Cancer 28 (12), 773-782, 2021
Mandates: US National Institutes of Health
Available somewhere: 65
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
Mandates: US National Institutes of Health, Fonds de recherche du Québec - Santé
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
TR Halfdanarson, KG Rabe, J Rubin, GM Petersen
Annals of oncology 19 (10), 1727-1733, 2008
Mandates: US National Institutes of Health
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
Y Wang, S Zhou, F Yang, X Qi, X Wang, X Guan, C Shen, N Duma, ...
JAMA oncology 5 (7), 1008-1019, 2019
Mandates: US National Institutes of Health
Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors
TR Halfdanarson, J Rubin, MB Farnell, CS Grant, GM Petersen
Endocrine-related cancer 15 (2), 409, 2008
Mandates: US National Institutes of Health
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial
JL Welsh, BA Wagner, TJ Van’t Erve, PS Zehr, DJ Berg, TR Halfdanarson, ...
Cancer chemotherapy and pharmacology 71, 765-775, 2013
Mandates: US National Institutes of Health
The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors
JR Strosberg, TR Halfdanarson, AM Bellizzi, JA Chan, JS Dillon, ...
Pancreas 46 (6), 707-714, 2017
Mandates: US National Institutes of Health
The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors
JR Howe, NB Merchant, C Conrad, XM Keutgen, J Hallet, JA Drebin, ...
Pancreas 49 (1), 1-33, 2020
Mandates: US National Institutes of Health
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ...
Annals of oncology 32 (6), 787-800, 2021
Mandates: US National Institutes of Health, Fonds de recherche du Québec - Santé
Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19
MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ...
JAMA oncology 7 (8), 1167-1175, 2021
Mandates: US National Institutes of Health, US Assistant Secretary for Preparedness …
The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors
TR Halfdanarson, JR Strosberg, L Tang, AM Bellizzi, EK Bergsland, ...
Pancreas 49 (7), 863-881, 2020
Mandates: US National Institutes of Health
Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study
DR Rivera, S Peters, OA Panagiotou, DP Shah, NM Kuderer, CY Hsu, ...
Cancer discovery 10 (10), 1514-1527, 2020
Mandates: US National Institutes of Health
Oral cancer chemotherapy: the critical interplay between patient education and patient safety
TR Halfdanarson, A Jatoi
Current oncology reports 12, 247-252, 2010
Mandates: US National Institutes of Health
Obesity adversely affects survival in pancreatic cancer patients
RR McWilliams, ME Matsumoto, PA Burch, GP Kim, TR Halfdanarson, ...
Cancer 116 (21), 5054-5062, 2010
Mandates: US National Institutes of Health
Evidence-based clinical practice guidelines for extramammary Paget disease
N Kibbi, JL Owen, B Worley, JX Wang, V Harikumar, MB Downing, ...
JAMA oncology 8 (4), 618-628, 2022
Mandates: US National Institutes of Health
Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study
TR Halfdanarson, WR Bamlet, RR McWilliams, TJ Hobday, PA Burch, ...
Pancreas 43 (8), 1219-1222, 2014
Mandates: US National Institutes of Health
Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors
JA Gilbert, LJ Adhikari, RV Lloyd, TR Halfdanarson, MH Muders, ...
Pancreas 42 (3), 411-421, 2013
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program